CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZYG11B (ImmuneEditome ID:79699)

1. Gene summary of enriched editing regions for ZYG11B

check button Gene summary
Gene informationGene symbol

ZYG11B

Gene ID

79699

GeneSynonymsZYG11
GeneCytomap

1p32.3

GeneTypeprotein-coding
GeneDescriptionprotein zyg-11 homolog B|zyg-11 homolog B
GeneModificationdate20230517
UniprotIDA8DPD7;Q9C0D3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:52790440-52790649:+ENST00000294353.6ENSG00000162378.11ZYG11BintronicMIRc,AluSx3chr1:52790440-52790649:+.alignment
chr1:52790440-52790649:+ENST00000545132.4ENSG00000162378.11ZYG11BintronicMIRc,AluSx3chr1:52790440-52790649:+.alignment
chr1:52817479-52818505:+ENST00000294353.6ENSG00000162378.11ZYG11Bintronic(TA)n,AluJb,AluSxchr1:52817479-52818505:+.alignment
chr1:52823155-52825812:+ENST00000294353.6ENSG00000162378.11ZYG11BUTR3(A)n,FLAM_C,AluJr,(T)n,AluSg4,AluSzchr1:52823155-52825812:+.alignment


Top

2. Tumor-specific enriched editing regions for ZYG11B


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:52823155-52825812:+BRCAEER9.5564e-36image
ENSG00000162378.11,ZYG11BBRCAEAG7.2822e-36image
chr1:52823155-52825812:+COADEER2.0507e-07image
ENSG00000162378.11,ZYG11BCOADEAG1.6056e-07image
chr1:52823155-52825812:+HNSCEER2.9672e-13image
ENSG00000162378.11,ZYG11BHNSCEAG2.9672e-13image
chr1:52823155-52825812:+KICHEER7.9130e-14image
ENSG00000162378.11,ZYG11BKICHEAG7.9130e-14image
chr1:52823155-52825812:+KIRCEER6.2806e-11image
ENSG00000162378.11,ZYG11BKIRCEAG4.3522e-11image
chr1:52823155-52825812:+LUADEER5.6123e-11image
ENSG00000162378.11,ZYG11BLUADEAG5.2959e-11image
chr1:52823155-52825812:+LUSCEER3.0427e-08image
ENSG00000162378.11,ZYG11BLUSCEAG3.0427e-08image
chr1:52823155-52825812:+STADEER8.4260e-04image
ENSG00000162378.11,ZYG11BSTADEAG8.2978e-04image
chr1:52823155-52825812:+THCAEER4.9137e-14image
ENSG00000162378.11,ZYG11BTHCAEAG4.9137e-14image
chr1:52823155-52825812:+UCECEER1.7539e-09image
ENSG00000162378.11,ZYG11BUCECEAG9.3508e-10image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr1:52823155-52825812:+BLCAPathEER5.8164e-043.1031e-020.1132image
ENSG00000162378.11,ZYG11BBLCAPathEAG1.2120e-033.5884e-020.1102image
ENSG00000162378.11,ZYG11BESCACliEAG2.5890e-022.8151e-02-0.3017image
chr1:52823155-52825812:+ESCACliEER2.6257e-022.8132e-02-0.3017image
chr1:52823155-52825812:+HNSCCliEER2.3077e-022.5218e-020.1059image
ENSG00000162378.11,ZYG11BHNSCCliEAG2.3077e-022.5218e-020.1059image
chr1:52823155-52825812:+KIRCPathEER5.7886e-044.1043e-050.1797image
ENSG00000162378.11,ZYG11BKIRCPathEAG5.0708e-043.2939e-050.1817image
ENSG00000162378.11,ZYG11BKIRPCliEAG1.3273e-022.4636e-030.2288image
chr1:52823155-52825812:+KIRPCliEER1.3273e-022.4636e-030.2288image
chr1:52823155-52825812:+LUSCPathEER2.2685e-023.5233e-020.0958image
ENSG00000162378.11,ZYG11BLUSCPathEAG2.2685e-023.5233e-020.0958image
ENSG00000162378.11,ZYG11BTHCAPathEAG7.0933e-044.2679e-030.1291image
chr1:52823155-52825812:+THCAPathEER7.0933e-044.2679e-030.1291image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZYG11B


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:52823155-52825812:+LGGEERENSG00000171316,CHD7-0.52112.8234e-313.6601e-35-0.5073imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184CHD7Macrophages_M1GSVA_HALLMARK_MYOGENESIS
chr1:52823155-52825812:+LGGEERENSG00000011258,MBTD1-0.51746.7036e-312.4078e-34-0.5019imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M1GSVA_HALLMARK_MYOGENESIS
chr1:52823155-52825812:+LGGEERENSG00000168137,SETD5-0.50541.2134e-291.9700e-32-0.4890imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAT_cells_CD8GSVA_HALLMARK_MYOGENESIS
chr1:52823155-52825812:+LGGEERENSG00000100426,ZBED4-0.50726.0512e-299.8241e-32-0.4841imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M0GSVA_HALLMARK_G2M_CHECKPOINT
chr1:52823155-52825812:+LGGEERENSG00000124766,SOX4-0.49841.7150e-285.8546e-29-0.4640imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;RTCB;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2;UPF1;VIM;YTHDC1;ZNF184SOX4Macrophages_M1GSVA_HALLMARK_G2M_CHECKPOINT
chr1:52823155-52825812:+LGGEERENSG00000254726,MEX3A-0.50203.2890e-281.6001e-28-0.4607imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RNF219;RTCB;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_G2M_CHECKPOINT
chr1:52823155-52825812:+LGGEERENSG00000234616,JRK-0.49553.8894e-285.8042e-28-0.4564imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M1GSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:52823155-52825812:+LGGEERENSG00000149639,SOGA1-0.50135.0705e-289.0436e-26-0.4390imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:52823155-52825812:+LGGEERENSG00000213222,AC093724.2-0.49255.0705e-284.3113e-29-0.4650imageNNNAMacrophages_M1GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr1:52823155-52825812:+LGGEERENSG00000139910,NOVA1-0.49835.0705e-281.1776e-28-0.4617imageNCELF2;CNBP;CSTF2T;DGCR8;DKC1;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;LIN28;LIN28B;NOP56;NOP58;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SRSF3;TAF15;TARDBP;TROVE2;U2AF2;UPF1;YTHDC1;ZNF184NAMacrophages_M1GSVA_HALLMARK_BILE_ACID_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for ZYG11B


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:52823155-52825812:+
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.49121.9663e-177.3867e-23-0.4866imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000162378.11,ZYG11B
BLCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.49291.6167e-177.3867e-23-0.4866imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:52823155-52825812:+
CESCEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.50448.0383e-132.5721e-19-0.5121imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000162378.11,ZYG11B
CESCEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.50447.1489e-132.5721e-19-0.5121imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:52823155-52825812:+
GBMEERIRENSG00000106077.14chr773736093:73737110:73737220:73737360-0.43081.1993e-043.0098e-08-0.4172imageNBUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000162378.11,ZYG11B
GBMEAGA5ENSG00000077809.8chr774728785:74728896:74716893:74716950:74716893:747189410.40484.4606e-044.3703e-080.4104imageNNNAMonocytesGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr1:52823155-52825812:+
GBMEERIRENSG00000204237.4chr1781665035:81665584:81666517:81666588-0.33864.2843e-034.5683e-08-0.4110imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;NONO;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAT_cells_gamma_deltaGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr1:52823155-52825812:+
GBMEERESENSG00000151292.13chr5123591318:123591414:123595038:123595134:123604723:123604830-0.39583.7869e-044.3924e-08-0.4174imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;ZNF184NAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:52823155-52825812:+
GBMEERIRENSG00000085872.10chr1916517888:16520507:16520825:165208730.39179.3312e-047.0436e-080.4035imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr1:52823155-52825812:+
GBMEERA5ENSG00000114354.8chr3100713642:100713869:100709424:100709431:100709424:100709721-0.40893.8233e-043.6313e-08-0.4138imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for ZYG11B


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:52823155-52825812:+ACCEERT_cells_CD4_memory_resting3.0513e-03-0.3647image
ENSG00000162378.11,ZYG11BACCEAGT_cells_CD4_memory_resting3.0513e-03-0.3647image
chr1:52823155-52825812:+BLCAEERMacrophages_M19.2909e-090.2961image
ENSG00000162378.11,ZYG11BBLCAEAGMacrophages_M11.0218e-080.2953image
chr1:52823155-52825812:+BRCAEERT_cells_regulatory_(Tregs)2.5885e-100.1938image
ENSG00000162378.11,ZYG11BBRCAEAGT_cells_regulatory_(Tregs)1.3645e-100.1967image
chr1:52823155-52825812:+CESCEERMacrophages_M03.4255e-04-0.2171image
ENSG00000162378.11,ZYG11BCESCEAGMacrophages_M03.4255e-04-0.2171image
chr1:52823155-52825812:+COADEERMacrophages_M13.0482e-030.1790image
ENSG00000162378.11,ZYG11BCOADEAGMacrophages_M15.8175e-030.1668image
ENSG00000162378.11,ZYG11BDLBCEAGNeutrophils2.9965e-020.4345image
chr1:52823155-52825812:+ESCAEERT_cells_regulatory_(Tregs)1.4888e-04-0.2946image
ENSG00000162378.11,ZYG11BESCAEAGT_cells_regulatory_(Tregs)1.5753e-04-0.2935image
chr1:52823155-52825812:+GBMEERMacrophages_M01.4301e-06-0.3640image
ENSG00000162378.11,ZYG11BGBMEAGMacrophages_M01.4301e-06-0.3640image
chr1:52823155-52825812:+HNSCEERT_cells_regulatory_(Tregs)1.6269e-02-0.1122image
ENSG00000162378.11,ZYG11BHNSCEAGT_cells_regulatory_(Tregs)1.6269e-02-0.1122image
chr1:52823155-52825812:+KICHEERPlasma_cells2.8999e-020.2731image
ENSG00000162378.11,ZYG11BKICHEAGPlasma_cells2.8999e-020.2731image
chr1:52823155-52825812:+KIRCEERT_cells_CD87.9394e-070.2517image
ENSG00000162378.11,ZYG11BKIRCEAGT_cells_CD81.2186e-060.2475image
chr1:52823155-52825812:+KIRPEERT_cells_CD4_memory_resting6.1384e-04-0.2135image
ENSG00000162378.11,ZYG11BKIRPEAGT_cells_CD4_memory_resting6.1384e-04-0.2135image
chr1:52823155-52825812:+LAMLEERB_cells_naive4.3386e-030.2566image
ENSG00000162378.11,ZYG11BLAMLEAGB_cells_naive7.0095e-040.3027image
chr1:52823155-52825812:+LGGEERMacrophages_M11.6791e-060.2088image
ENSG00000162378.11,ZYG11BLGGEAGMacrophages_M11.6791e-060.2088image
chr1:52823155-52825812:+LIHCEERT_cells_CD86.1476e-030.1592image
ENSG00000162378.11,ZYG11BLIHCEAGT_cells_CD86.1476e-030.1592image
chr1:52823155-52825812:+LUADEERT_cells_CD4_memory_activated1.9016e-050.1898image
ENSG00000162378.11,ZYG11BLUADEAGT_cells_CD4_memory_activated1.6128e-050.1914image
chr1:52823155-52825812:+LUSCEERT_cells_CD4_memory_activated2.9168e-100.2814image
ENSG00000162378.11,ZYG11BLUSCEAGT_cells_CD4_memory_activated2.9168e-100.2814image
chr1:52823155-52825812:+MESOEERMast_cells_resting9.3271e-03-0.2945image
ENSG00000162378.11,ZYG11BMESOEAGMast_cells_resting9.3271e-03-0.2945image
chr1:52823155-52825812:+OVEERT_cells_CD81.1966e-040.2236image
ENSG00000162378.11,ZYG11BOVEAGT_cells_CD81.1165e-040.2246image
chr1:52823155-52825812:+PAADEERMacrophages_M03.0219e-030.2288image
ENSG00000162378.11,ZYG11BPAADEAGMacrophages_M03.0219e-030.2288image
chr1:52823155-52825812:+PRADEERT_cells_regulatory_(Tregs)2.9890e-060.2145image
ENSG00000162378.11,ZYG11BPRADEAGT_cells_regulatory_(Tregs)3.2977e-050.1911image
chr1:52823155-52825812:+SARCEERT_cells_CD89.2175e-030.1695image
ENSG00000162378.11,ZYG11BSARCEAGT_cells_CD89.2369e-030.1695image
chr1:52823155-52825812:+SKCMEERT_cells_CD87.3161e-120.3197image
ENSG00000162378.11,ZYG11BSKCMEAGT_cells_CD86.5747e-120.3203image
chr1:52823155-52825812:+STADEERMacrophages_M12.8640e-040.1870image
ENSG00000162378.11,ZYG11BSTADEAGMacrophages_M13.0664e-040.1861image
chr1:52823155-52825812:+TGCTEERMacrophages_M22.2228e-05-0.3538image
ENSG00000162378.11,ZYG11BTGCTEAGMacrophages_M22.2228e-05-0.3538image
chr1:52823155-52825812:+THCAEERT_cells_regulatory_(Tregs)5.9346e-070.2235image
ENSG00000162378.11,ZYG11BTHCAEAGT_cells_regulatory_(Tregs)5.9346e-070.2235image
chr1:52823155-52825812:+THYMEERNK_cells_resting1.3656e-020.2782image
ENSG00000162378.11,ZYG11BTHYMEAGNK_cells_resting1.3656e-020.2782image
chr1:52823155-52825812:+UCSEEREosinophils1.4807e-02-0.3462image
ENSG00000162378.11,ZYG11BUCSEAGEosinophils1.4807e-02-0.3462image
ENSG00000162378.11,ZYG11BUVMEAGT_cells_regulatory_(Tregs)4.4667e-050.5214image


Top

6. Enriched editing regions and immune gene sets for ZYG11B


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr1:52823155-52825812:+KIRCEER9.7067e-060.22626.9655e-040.17443.9766e-020.10621.1319e-020.1307image
ENSG00000162378.11,ZYG11BLUADEAG1.1963e-070.23381.0249e-060.21631.1555e-050.19462.0298e-040.1653image
chr1:52823155-52825812:+LUADEER1.0831e-070.23461.1624e-060.21521.0438e-050.19551.6428e-040.1676image
ENSG00000162378.11,ZYG11BPAADEAG4.5442e-050.31106.4046e-040.26237.3822e-050.30274.4931e-030.2195image
chr1:52823155-52825812:+PAADEER4.5442e-050.31106.4046e-040.26237.3822e-050.30274.4931e-030.2195image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:52823155-52825812:+ACCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER2.0563e-020.2890image
ENSG00000162378.11,ZYG11BACCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.0563e-020.2890image
chr1:52823155-52825812:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4862e-130.3753image
ENSG00000162378.11,ZYG11BBLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.6911e-130.3745image
chr1:52823155-52825812:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.8580e-250.3134image
ENSG00000162378.11,ZYG11BBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0109e-240.3098image
chr1:52823155-52825812:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.2237e-130.4256image
ENSG00000162378.11,ZYG11BCESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.2237e-130.4256image
ENSG00000162378.11,ZYG11BCHOLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.9962e-03-0.5416image
chr1:52823155-52825812:+CHOLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.9962e-03-0.5416image
ENSG00000162378.11,ZYG11BCOADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.9538e-05-0.2435image
chr1:52823155-52825812:+COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.9876e-050.2502image
ENSG00000162378.11,ZYG11BESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.4430e-04-0.2696image
chr1:52823155-52825812:+ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.5999e-04-0.2729image
ENSG00000162378.11,ZYG11BGBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9678e-110.4905image
chr1:52823155-52825812:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9678e-110.4905image
chr1:52823155-52825812:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1946e-090.2722image
ENSG00000162378.11,ZYG11BHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1946e-090.2722image
ENSG00000162378.11,ZYG11BKICHGSVA_HALLMARK_APICAL_SURFACEEAG2.0216e-03-0.3788image
chr1:52823155-52825812:+KICHGSVA_HALLMARK_APICAL_SURFACEEER2.0216e-03-0.3788image
ENSG00000162378.11,ZYG11BKIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.0410e-090.3032image
chr1:52823155-52825812:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1710e-090.3076image
chr1:52823155-52825812:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER4.5257e-09-0.3575image
ENSG00000162378.11,ZYG11BKIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.5257e-09-0.3575image
ENSG00000162378.11,ZYG11BLAMLGSVA_HALLMARK_PEROXISOMEEAG2.9195e-03-0.2673image
chr1:52823155-52825812:+LAMLGSVA_HALLMARK_PEROXISOMEEER2.9902e-03-0.2666image
ENSG00000162378.11,ZYG11BLGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.8085e-24-0.4282image
chr1:52823155-52825812:+LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.8085e-24-0.4282image
chr1:52823155-52825812:+LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER4.5453e-03-0.1648image
ENSG00000162378.11,ZYG11BLIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.5453e-03-0.1648image
ENSG00000162378.11,ZYG11BLUADGSVA_HALLMARK_MYC_TARGETS_V1EAG1.2501e-080.2509image
chr1:52823155-52825812:+LUADGSVA_HALLMARK_MYC_TARGETS_V1EER1.0790e-080.2520image
ENSG00000162378.11,ZYG11BLUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.9319e-070.2222image
chr1:52823155-52825812:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.9319e-070.2222image
ENSG00000162378.11,ZYG11BMESOGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.6139e-02-0.2535image
chr1:52823155-52825812:+MESOGSVA_HALLMARK_PROTEIN_SECRETIONEER2.6139e-02-0.2535image
chr1:52823155-52825812:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.1077e-100.3558image
ENSG00000162378.11,ZYG11BOVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.8204e-100.3564image
chr1:52823155-52825812:+PAADGSVA_HALLMARK_P53_PATHWAYEER8.8389e-050.2995image
ENSG00000162378.11,ZYG11BPAADGSVA_HALLMARK_P53_PATHWAYEAG8.8389e-050.2995image
chr1:52823155-52825812:+PCPGGSVA_HALLMARK_NOTCH_SIGNALINGEER2.9151e-03-0.2383image
ENSG00000162378.11,ZYG11BPCPGGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.9151e-03-0.2383image
chr1:52823155-52825812:+PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER5.8058e-10-0.2819image
ENSG00000162378.11,ZYG11BPRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.0783e-10-0.2889image
ENSG00000162378.11,ZYG11BREADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2500e-020.2377image
chr1:52823155-52825812:+READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2500e-020.2377image
ENSG00000162378.11,ZYG11BSARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.8461e-070.3239image
chr1:52823155-52825812:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.8639e-070.3239image
chr1:52823155-52825812:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.0008e-130.3361image
ENSG00000162378.11,ZYG11BSKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.5732e-130.3355image
chr1:52823155-52825812:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.5637e-110.3282image
ENSG00000162378.11,ZYG11BSTADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2002e-100.3258image
chr1:52823155-52825812:+TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.3509e-090.4730image
ENSG00000162378.11,ZYG11BTGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.3509e-090.4730image
ENSG00000162378.11,ZYG11BTHCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.5085e-160.3562image
chr1:52823155-52825812:+THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.5085e-160.3562image
chr1:52823155-52825812:+THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.6717e-050.4564image
ENSG00000162378.11,ZYG11BTHYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.6717e-050.4564image
chr1:52823155-52825812:+UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.6709e-030.2457image
ENSG00000162378.11,ZYG11BUCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2363e-020.2109image
chr1:52823155-52825812:+UCSGSVA_HALLMARK_MYOGENESISEER1.6511e-04-0.5128image
ENSG00000162378.11,ZYG11BUCSGSVA_HALLMARK_MYOGENESISEAG1.6511e-04-0.5128image
ENSG00000162378.11,ZYG11BUVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.7756e-070.6074image


Top

7. Enriched editing regions and drugs for ZYG11B


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:52823155-52825812:+ACCABT.263EER4.0868e-030.3542image
ENSG00000162378.11,ZYG11BACCABT.263EAG4.0868e-030.3542image
ENSG00000162378.11,ZYG11BBLCACGP.60474EAG4.2391e-16-0.4099image
chr1:52823155-52825812:+BLCACGP.60474EER2.2540e-16-0.4134image
chr1:52823155-52825812:+BRCAA.443654EER8.0345e-14-0.2282image
ENSG00000162378.11,ZYG11BBRCAA.443654EAG4.7058e-14-0.2302image
ENSG00000162378.11,ZYG11BCESCBMS.536924EAG1.0272e-07-0.3181image
chr1:52823155-52825812:+CESCBMS.536924EER1.0272e-07-0.3181image
chr1:52823155-52825812:+CHOLBIBW2992EER3.3935e-04-0.6106image
ENSG00000162378.11,ZYG11BCHOLBIBW2992EAG3.3935e-04-0.6106image
chr1:52823155-52825812:+COADGefitinibEER1.0601e-05-0.2635image
ENSG00000162378.11,ZYG11BCOADGefitinibEAG1.9815e-06-0.2837image
ENSG00000162378.11,ZYG11BDLBCAZD.2281EAG9.1490e-04-0.6214image
ENSG00000162378.11,ZYG11BESCACGP.60474EAG4.5047e-03-0.2228image
chr1:52823155-52825812:+ESCACGP.60474EER4.4835e-03-0.2229image
ENSG00000162378.11,ZYG11BGBMBIBW2992EAG9.1712e-10-0.4527image
chr1:52823155-52825812:+GBMBIBW2992EER9.1712e-10-0.4527image
chr1:52823155-52825812:+HNSCABT.263EER4.3004e-080.2528image
ENSG00000162378.11,ZYG11BHNSCABT.263EAG4.3004e-080.2528image
ENSG00000162378.11,ZYG11BKICHABT.263EAG2.7620e-070.5908image
chr1:52823155-52825812:+KICHABT.263EER2.7620e-070.5908image
ENSG00000162378.11,ZYG11BKIRCGDC.0449EAG4.9941e-16-0.4029image
chr1:52823155-52825812:+KIRCGDC.0449EER3.6252e-17-0.4170image
ENSG00000162378.11,ZYG11BKIRPAZD6482EAG2.6870e-100.3830image
chr1:52823155-52825812:+KIRPAZD6482EER2.6870e-100.3830image
ENSG00000162378.11,ZYG11BLAMLGDC0941EAG2.0674e-03-0.2763image
chr1:52823155-52825812:+LAMLAKT.inhibitor.VIIIEER2.1009e-03-0.2759image
ENSG00000162378.11,ZYG11BLGGKIN001.135EAG4.0004e-27-0.4499image
chr1:52823155-52825812:+LGGKIN001.135EER4.0004e-27-0.4499image
chr1:52823155-52825812:+LIHCDasatinibEER5.2646e-04-0.2081image
ENSG00000162378.11,ZYG11BLIHCDasatinibEAG5.2646e-04-0.2081image
ENSG00000162378.11,ZYG11BLUADCGP.60474EAG2.6063e-08-0.2455image
chr1:52823155-52825812:+LUADCGP.60474EER1.8779e-08-0.2479image
ENSG00000162378.11,ZYG11BLUSCLFM.A13EAG2.3194e-050.1911image
chr1:52823155-52825812:+LUSCLFM.A13EER2.3194e-050.1911image
ENSG00000162378.11,ZYG11BMESOAICAREAG3.3985e-040.3978image
chr1:52823155-52825812:+MESOAICAREER3.3985e-040.3978image
chr1:52823155-52825812:+OVBexaroteneEER1.8582e-080.3223image
ENSG00000162378.11,ZYG11BOVBexaroteneEAG2.2006e-080.3207image
chr1:52823155-52825812:+PAADEHT.1864EER3.0941e-050.3221image
ENSG00000162378.11,ZYG11BPAADEHT.1864EAG3.0941e-050.3221image
chr1:52823155-52825812:+PCPGAZD6482EER6.7637e-050.3154image
ENSG00000162378.11,ZYG11BPCPGAZD6482EAG6.7637e-050.3154image
ENSG00000162378.11,ZYG11BPRADGNF.2EAG4.9118e-13-0.3268image
chr1:52823155-52825812:+PRADGNF.2EER6.2230e-13-0.3254image
ENSG00000162378.11,ZYG11BREADJNK.9LEAG5.7152e-03-0.2860image
chr1:52823155-52825812:+READJNK.9LEER5.7152e-03-0.2860image
ENSG00000162378.11,ZYG11BSARCCisplatinEAG3.2742e-06-0.2982image
chr1:52823155-52825812:+SARCCisplatinEER3.2734e-06-0.2982image
chr1:52823155-52825812:+SKCMCI.1040EER6.2147e-10-0.2900image
ENSG00000162378.11,ZYG11BSKCMCI.1040EAG6.9847e-10-0.2892image
chr1:52823155-52825812:+STADDasatinibEER9.3913e-04-0.1717image
ENSG00000162378.11,ZYG11BSTADDasatinibEAG9.5933e-04-0.1714image
ENSG00000162378.11,ZYG11BTGCTAZD6244EAG9.7576e-07-0.4041image
chr1:52823155-52825812:+TGCTAZD6244EER9.7576e-07-0.4041image
chr1:52823155-52825812:+THCACCT007093EER5.1793e-300.4835image
ENSG00000162378.11,ZYG11BTHCACCT007093EAG5.1793e-300.4835image
ENSG00000162378.11,ZYG11BTHYMEmbelinEAG2.8371e-070.5428image
chr1:52823155-52825812:+THYMEmbelinEER2.8371e-070.5428image
ENSG00000162378.11,ZYG11BUCECGDC.0449EAG1.3462e-07-0.4278image
chr1:52823155-52825812:+UCECGDC.0449EER2.1148e-03-0.2595image
ENSG00000162378.11,ZYG11BUCSErlotinibEAG2.8994e-05-0.5597image
chr1:52823155-52825812:+UCSErlotinibEER2.8994e-05-0.5597image
ENSG00000162378.11,ZYG11BUVMCGP.60474EAG9.1984e-09-0.6830image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType